Mitumomab ? Monoclonal antibody Type Whole antibody Source Mouse Target GD3 ganglioside Clinical data Pregnancy cat. ? Legal status ? Identifiers CAS number ATC code None KEGG Chemical data Formula ? (what is this?)
Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009[update], the drug is undergoing Phase III clinical trials.
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.